Recognizing these developments, the 2024 KDIGO CKD guideline recommends initiating SGLT2 inhibitors in CKD patients (with or without T2D) with an eGFR ≥ 20 mL/min, cementing their role as a mainstay therapy alongside RAAS blockade [7]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.